SHL Telemedicine Ltd. engages in the development and market of advanced personal telemedicine solutions, which focuses on cardiovascular and related diseases. Personal telemedicine is the transmission of medical data by an individual, from a remote location, to a medical call center through telecommunication networks. SHL’s platform offers solutions to subscribing patients, health insurance companies, hospitals, clinics, physicians and other health care providers. Its solutions for healthcare professionals include: CHF monitoring service that supports patients suffering from Congestive Heart Failure; COPD monitoring service that supports patients suffering from Chronic Obstructive Pulmonary Disease, and Readmission Solutions for reducing heart-related readmissions. Its consumers' solutions include Cardiac Monitoring Service.
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for SHMLF. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: SHMLF is a Sell candidate.
SHMLF stock price ended at $4.84 on 木曜日, after rising 0.00%
On the latest trading day Feb 05, 2026, the stock price of SHMLF rose by 0.00%, climbing from $4.84 to $4.84. During the session, the stock saw a volatility of 0.00%, with prices oscillating between a daily low of $4.84 and a high of $4.84. Notably, trading volume dropped by -- shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of -- shares were traded, equating to a market value of approximately $79.3M.